Bone cancer research
Osteosarcoma and Ewing's sarcoma
Bone cancer occurs when bone cells become abnormal and grow out of control. It is rare and there are several types, given its genetic heterogeneity.
Certain bone cancers occur more frequently in children and young adults than in adults. Generally, these tumors are malignant, grow rapidly and are highly capable of developing metastases, limiting treatment options. Together with childhood brain tumors, they are the leading cause of cancer mortality in children.
The causes of these tumors are unknown, but it is known that some genetic diseases predispose to them.
Among these, the most frequent in children is osteosarcoma, which originates most frequently in the arms and legs. In adolescents and young adults, Ewing's sarcoma is more common and, in addition to the bones, it can also form in soft tissue, such as muscles or other supporting tissues of the body.
We dream of curing bone tumors
Treatment options have increased significantly in recent years, but much remains to be discovered.
To deepen our understanding of the underlying biology of these tumors and the mechanisms involved in their development.
We seek to find new biomarkers of the disease and to develop new specific therapeutic strategies targeting these tumors.
We work closely with researchers and clinicians to rapidly translate findings from the laboratory to the patient.
How do we research bone cancer?
Cima's research on bone cancer is part of the Neuro-oncology, Sarcomas, and Paediatric Tumours Research Area of the Clínica Universidad de Navarra Cancer Centre.
Our bone cancer research group
REFERENCES IN TRANSLATIONAL RESEARCH
Advanced Therapies for Paediatric Solid Tumours Research Group
Reference team in the translational research of bone tumors with special interest in those that develop in childhood and adolescence. Its objective is to understand the causes of the disease in order to identify new therapeutic alternatives and develop innovative strategies for its treatment.
It is part of the Solid Tumors Program.